Atabak Mokari - Feb 28, 2025 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Role: Chief Financial Officer
Signature: /s/ Joseph Douglas Lyon, as attorney-in-fact for Atabak Mokari.
Stock symbol: CORT
Transactions as of: Feb 28, 2025
Transactions value $: -$108
Form type: 4
Date filed: 3/4/2025, 07:34 PM
Previous filing: Dec 4, 2024
Next filing: Jun 4, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CORT	Common Stock	Tax liability	-$13.8K	-228	-1.78%	$60.58	12.6K	Mar 3, 2025	Direct	F1, F2, F3
transaction	CORT	Common Stock	Award	$13.7K	+232	+1.85%	$59.07	12.8K	Mar 3, 2025	Direct	F3, F4, F5
transaction	CORT	Common Stock	Award	$0	+232	+1.81%	$0.00	13K	Mar 3, 2025	Direct	F3, F6

Showing 1 to 3 of 3 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CORT	Stock option (right to buy)	Award	$0	+140K		$0.00	140K	Feb 28, 2025	Common Stock	140K	$60.58	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
F2	The closing price on February 28, 2025 was used to calculate the withholding obligation.
F3	Includes 1,448 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 400 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 231 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F4	The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 3, 2025.
F5	In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F6	Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
F7	Exercise ratably in equal installments on each monthly anniversary of February 28, 2025 over a four-year period subject to the Reporting Person's continued service through each vesting date.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.